TipRanks on MSN
Eli Lilly’s phase 2 study on imlunestrant: A potential game-changer in breast cancer treatment
Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is ...
Eli Lilly's retatrutide compound mimics three hormones associated with hunger regulation. "Lilly Reports Positive Results in Next-Gen Obesity Drug Trial -- Update," at 8:27 a.m. ET on Dec. 11, ...
Eli Lilly’s retatrutide exceeds expectations in Phase III, capping off a sparkling 2025 for the obesity titan; an internal ...
Woman's World on MSN
New weight loss drug beats Ozempic and eases joint pain with 'insane' results, doctors say
Brace yourselves, Ozempic and Zepound. Eli Lilly just released a jaw-dropping sneak peek from the final phases of testing for ...
In this video, Matthew S. Davids, MD, spoke about the BRUIN-314 trial, one of the first head-to-head studies to compare pirtobrutinib, a noncovalent Bruton tyrosine kinase inhibitor, with ibrutinib, a ...
Combining elacestrant with targeted agents produced “clinically meaningful” outcomes for patients with locally advanced or metastatic ER-positive/HER2-negative breast cancer who have received at least ...
Eli Lilly and Company has delivered significant positive developments this week, though its shares experienced a minor pullback in Wednesday's trading sessio ...
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...
9hon MSN
Exclusive: US FDA taps Merck drugs with blockbuster sales potential for national priority vouchers
The U.S. Food and Drug Administration is moving to fast-track reviews of two experimental Merck drugs with multibillion-dollar potential, according to internal documents seen by Reuters.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback